Success Story: EB1A Approved with Premium Processing Service! Our Firm Assisted an Indian Hematologist and Medical Oncologist in Securing Success
Client’s Testimonial:
“Thank you so much for working with me to have this approved. It has been a long journey and a lot of hard work to get to where we are today. My family and I are thrilled to have received this approval. We cannot thank your team enough for preparing my case and getting it approved. I am forever grateful. This is the best news we have received so far regarding our status in the USA.”
On November 6th, 2025, we received another EB-1A (Alien of Extraordinary Ability) approval for a Hematologist and Medical Oncologist in the Field of Oncology (Approval Notice).
General Field: Oncology
Position at the Time of Case Filing: Hematologist and Medical Oncologist
Country of Origin: India
State of Residence at the Time of Filing: Iowa
Approval Notice Date: November 6th, 2025
Processing Time: 1 month, 8 days (Premium Processing Upgrade Requested)
Case Summary:
North America Immigration Law Group (NAILG) is pleased to share the successful approval of an EB1A petition for a distinguished expert in oncology whose work advances malignant hematology, benign hematology, and medical oncology. The client, who holds an MBBS and currently serves in a clinical and research role within the oncology sector, approached NAILG seeking support in securing permanent residency through the EB1A (Alien of Extraordinary Ability) category. After a thorough review of the client’s achievements and impact, NAILG prepared a compelling petition that resulted in the approval of the I-140 EB1A filing. This approval underscores the client’s extraordinary influence in cancer research and clinical care.
Accomplishments and Expertise
The client has established a strong reputation as a leading researcher in oncology, with particular expertise in malignant and benign hematology. Much of the client’s work focuses on improving the understanding, diagnosis, and treatment of complex hematologic cancers. The client’s contributions have been especially influential in examining risk factors, treatment patterns, and clinical outcomes related to central nervous system involvement in Burkitt lymphoma, a rare but aggressive malignancy with limited therapeutic guidance. Additionally, the client’s work advances treatment strategies for hemolytic uremic syndrome, hematologic malignancies, and other high-risk oncologic conditions.
In support of the EB1A petition, NAILG highlighted several objective achievements, including:
-
16 peer-reviewed journal articles (including 3 as first author)
-
23 published abstracts (including 6 as first author)
-
4 book chapters, including 2 as first author
-
Over 50 completed peer reviews, reflecting the client’s authority and recognition in the field
-
310 citations, demonstrating widespread reliance on the client’s work by other independent scientists
Letters of Recommendation
To further support the petition, NAILG obtained four letters of recommendation from highly regarded experts in oncology and hematology. These independent recommenders attested to the significance of the client’s discoveries, the originality of the client’s research contributions, and the measurable benefit the client provides to the broader oncology community.
“Given the importance of improving quality of life for cancer patients, [Client’s] work offers essential insights that position him as an irreplaceable asset in the management of these diseases in the US.”
EB1A Approval and Outlook
The client’s EB1A petition was approved after USCIS determined that the body of evidence clearly established extraordinary ability in oncology and a sustained record of national and international acclaim. The client’s continued work in malignant hematology and oncology promises to support improved cancer diagnosis, treatment, and patient outcomes—areas of strong national importance for the United States.
NAILG is honored to have represented the client in this successful EB1A petition and looks forward to seeing the continued contributions the client will make to advancing cancer care and scientific discovery.